Pear gearing up to sell products solo as Sandoz backs out of digital deal

While Sandoz has pulled out of its commercialization deal with Pear, the digital therapy pioneer believes it is well positioned to commercialize its flagship digital therapeutics independently.

Pear Therapeutics Inc. will assume sole commercial responsibility for its two marketed prescription therapeutics, reSET and reSET-O, 18 months after the partners teamed up in a co-promotion deal for the therapies.

reSET and reSET-O, which were approved by

Read the full 630 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE